Join to view full profile
7130 N Millbrook AveFresno, CA 93720
Phone+1 559-326-1222
Fax+1 559-326-1230
Dr. Hager is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Steven Hager, DO, is an oncology specialist based in Fresno, CA, with extensive experience in multiple myeloma and lymphoma. He completed his fellowship in Hematology and Medical Oncology at the Naval Medical Center, San Diego, and his internal medicine residency at the National Capital Consortium. He has published research articles on myelofibrosis, non-small-cell lung cancer, and novel growth factors in cancer therapy. Dr. Hager has been involved in several clinical trials, including therapies for squamous cell carcinoma, ovarian cancer, lung cancer, and myelodysplastic syndromes. He received the CMS Meaningful Use Stage 1 Certification from ARIA Medical Oncology EMR in 2012.
Education & Training
Naval Medical Center (San Diego)Fellowship, Hematology and Medical Oncology, 1993 - 1996
National Capital ConsortiumResidency, Internal Medicine, 1988 - 1991
NYIT College Of Osteopathic MedicineClass of 1984
Certifications & Licensure
CA State License 2002 - 2027
WY State License 2026 - 2027
VA State License 1999 - 2016
FL State License 1991 - 2004
NC State License 2001 - 2004
MI State License 1984 - 1985
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012-2017
- CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Radiation Oncology), Varian Medical Systems, 2012-2017
Clinical Trials
- Bioequivalence Study of Azacitidine for Injection in Myelodysplastic Syndrome (MDS) Patients
- Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor Start of enrollment: 2012 Aug 07
- Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer Start of enrollment: 2013 Mar 25
Publications & Presentations
PubMed
- 3 citationsValidation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer.Alessandra Fabi, Steven Hager, Laura Lourdes, Chiara Gandini, Elizabeth M Gavioli
The Oncologist. 2025-10-01 - 24 citationsGarsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12...Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, Pamela N Munster, Yanhong Deng
Signal Transduction and Targeted Therapy. 2025-06-17 - 14 citationsPhase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.Abdulraheem Yacoub, Uma Borate, Raajit K Rampal, Haris Ali, Eunice S Wang
Blood Advances. 2024-03-26
Press Mentions
4/20, the Marijuana Holiday, ExplainedApril 20th, 2021
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
